Alpha Tau Medical (DRTS) – Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Alpha Tau Medical (NASDAQ: DRTS) recently:

  • 11/17/2026 – Alpha Tau Medical had its “buy” rating reaffirmed by UBS Group.
  • 11/17/2026 – Alpha Tau Medical had its “buy” rating reaffirmed by HC Wainwright. They now have a $16.00 price target on the stock.
  • 11/11/2026 – Alpha Tau Medical was upgraded by Piper Sandler from “neutral” to “overweight”. They now have a $22.00 price target on the stock, up from $8.00.
  • 11/9/2026 – Alpha Tau Medical was upgraded by Zacks Research from “strong sell” to “hold”.
  • 10/20/2026 – Alpha Tau Medical had its “buy” rating reaffirmed by HC Wainwright. They now have a $16.00 price target on the stock.
  • 10/15/2026 – Alpha Tau Medical had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Alpha Tau Medical Price Performance

Shares of DRTS stock traded up $0.12 on Tuesday, reaching $12.09. The company had a trading volume of 1,085,680 shares, compared to its average volume of 597,179. The business’s 50-day moving average is $14.00 and its 200 day moving average is $10.94. Alpha Tau Medical Ltd. has a one year low of $3.43 and a one year high of $15.79. The company has a quick ratio of 7.79, a current ratio of 11.09 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $1.09 billion, a PE ratio of -11.62 and a beta of 1.28.

Insider Transactions at Alpha Tau Medical

In related news, CFO Raphi Levy sold 2,871 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $15.00, for a total value of $43,065.00. Following the completion of the transaction, the chief financial officer owned 90,180 shares of the company’s stock, valued at $1,352,700. This represents a 3.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 39.50% of the stock is currently owned by corporate insiders.

Alpha Tau Medical Ltd. is an Israel-based medical technology company developing Alpha DaRT, an investigational radiation treatment for solid tumors. The company was founded in 2016 and is headquartered in Jerusalem. Alpha DaRT uses tiny sources containing radium-224 that are placed directly inside a tumor. As the material decays, it releases alpha-emitting atoms that travel a short distance through the tumor, aiming to destroy cancer cells while limiting exposure to nearby healthy tissue. The company is conducting clinical development of Alpha DaRT for multiple types of solid tumors, with research and clinical trials in Israel and other countries, including the United States and Japan.

Read More

Receive News & Ratings for Alpha Tau Medical Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical Ltd and related companies with MarketBeat.com's FREE daily email newsletter.